Physician profile
Pierre A Puente
NPI 1376836197
$2,193.70
in general payments reported to CMS, 2019-2025
12 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $257 · 2021: $191 · 2022: $328 · 2023: $346 · 2024: $283 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $784.43 | 2019-2025 | Sublocade |
| Orexo US, INC. | $269.97 | 2019-2025 | Zubsolv |
| Uswm, LLC | $254.69 | 2021-2022 | |
| Ucb, INC. | $242.58 | 2019-2023 | Briviact |
| Braeburn INC. | $171.03 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $141.75 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $123.63 | 2020-2025 | |
| Alkermes, INC. | $96.04 | 2019-2024 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $58.40 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $21.96 | 2023 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $16.32 | 2024 | Airsupra |
| Masimo Corporation | $12.90 | 2023 | Emma and Isa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.